Lillich Felix F, Imig John D, Proschak Ewgenij
Institute of Pharmaceutical Chemistry, Goethe-University of Frankfurt, Frankfurt, Germany.
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, United States.
Front Pharmacol. 2021 Mar 12;11:554961. doi: 10.3389/fphar.2020.554961. eCollection 2020.
Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of efficacy and future perspective for multi-target drugs in MetS are discussed.
代谢综合征（MetS）是一种在全球范围内高度流行的疾病集群。它需要对包括II型糖尿病、高血压和血脂异常等单一病症以及相关合并症进行多药联合治疗。使用多种药物的复杂治疗方案会导致药物相互作用以及患者依从性不足，从而导致疾病管理不善。多靶点方法旨在减少联合用药并提高疗效。本综述总结了为开发用于治疗代谢综合征的多靶点配体所做的药物化学研究工作。讨论了在代谢综合征中多靶点药物的疗效背景下不同药理靶点组合以及未来前景。
